These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 18027263)

  • 1. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
    Ratnam I; Franklin C; Spelman DW
    Pathology; 2007 Dec; 39(6):586-8. PubMed ID: 18027263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM; Al-Khattaf AS; Kambal AM
    Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
    Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
    Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
    Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
    Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
    Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P; Finch R
    Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
    Arya SC; Agarwal N
    Saudi Med J; 2008 Nov; 29(11):1558-60. PubMed ID: 18998000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of multidrug resistance: the treatment of gram-negative rod infections.
    Levin AS; Oliveira MS
    Shock; 2008 Oct; 30 Suppl 1():30-3. PubMed ID: 18704012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of colistin in gram-negative bacteria.
    Tan TY; Ng SY
    Singapore Med J; 2006 Jul; 47(7):621-4. PubMed ID: 16810437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.